Prospective clinical investigation of the efficacy of combination radiotherapy with immune checkpoint inhibition.

[1]  N. Wolmark,et al.  Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[2]  N. Sanfilippo,et al.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. , 2021, The Lancet. Oncology.

[3]  R. Bell,et al.  Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma , 2021, Journal for ImmunoTherapy of Cancer.

[4]  A. Murphy,et al.  Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.

[5]  J. Ajani,et al.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. , 2021, The New England journal of medicine.

[6]  K. Harrington,et al.  Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.

[7]  Emily M. Thrash,et al.  A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer , 2021, Clinical Cancer Research.

[8]  U. Dafni,et al.  Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Joe Y. Chang,et al.  Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.

[10]  R. Weichselbaum,et al.  Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial , 2020, Clinical Cancer Research.

[11]  Joe Y. Chang,et al.  Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.

[12]  T. Meirson,et al.  Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors , 2020, JAMA network open.

[13]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[14]  N. Lee,et al.  Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Agarwal,et al.  Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. , 2020, European urology.

[16]  M. Loda,et al.  Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung , 2020, Journal for ImmunoTherapy of Cancer.

[17]  P. Thompson,et al.  Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. V. van Zelm,et al.  Stereotactic radiotherapy combined with immunotherapy against metastatic melanoma: Long term results of a phase I clinical trial. , 2020, International journal of radiation oncology, biology, physics.

[19]  W. Urba,et al.  Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma , 2020, Journal for immunotherapy of cancer.

[20]  Z. Morris,et al.  Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments. , 2020, Seminars in radiation oncology.

[21]  C. Simone,et al.  Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. , 2020, JAMA oncology.

[22]  E. Winer,et al.  A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. , 2020, Clinical breast cancer.

[23]  H. McArthur,et al.  A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer , 2019, Cancer.

[24]  S. Jolly,et al.  A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. , 2019, International journal of radiation oncology, biology, physics.

[25]  Minetta C. Liu,et al.  A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. , 2019, Thyroid : official journal of the American Thyroid Association.

[26]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[27]  C. Langer,et al.  Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. , 2019, JAMA oncology.

[28]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[29]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[30]  E. Goetghebeur,et al.  Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.

[31]  B. Neel,et al.  Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer , 2019, Oncotarget.

[32]  S. Markovina,et al.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. , 2019, Brachytherapy.

[33]  S. Loi,et al.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[35]  E. Wherry,et al.  A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours , 2018, British Journal of Cancer.

[36]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[37]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[38]  J. Welsh,et al.  Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. , 2018, International journal of radiation oncology, biology, physics.

[39]  R. Huddart,et al.  Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. , 2018, International journal of radiation oncology, biology, physics.

[40]  B. Mahal,et al.  Safety of combining radiotherapy with immune-checkpoint inhibition , 2018, Nature Reviews Clinical Oncology.

[41]  B. Comin-Anduix,et al.  Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer , 2018, Clinical Cancer Research.

[42]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[43]  Manish R. Sharma,et al.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Goetghebeur,et al.  Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. , 2017, International journal of radiation oncology, biology, physics.

[45]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[46]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[47]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[48]  F. Hodi,et al.  Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. , 2017, International journal of radiation oncology, biology, physics.

[49]  S. Demaria,et al.  Barriers to Radiation-Induced In Situ Tumor Vaccination , 2017, Front. Immunol..

[50]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[51]  James J. Evans,et al.  Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[52]  C. Drake,et al.  Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy , 2016 .

[53]  Joe Y. Chang,et al.  Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.

[54]  S. Swetter,et al.  A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. , 2015, International journal of radiation oncology, biology, physics.

[55]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[56]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[57]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[58]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[59]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[60]  Y. Yamada,et al.  Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma , 2013, Cancer Immunology Research.

[61]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[62]  Joe Y. Chang,et al.  Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC , 2020 .

[63]  A. Al-Mamgani,et al.  Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[64]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.